12-Week Results of a Phase 2b Dose-Ranging Study of Baricitinib (LY3009104) in Combination with Traditional DMARDs in Patients with RA

Maria Vinall

doi:10.1177/155989771209010

Maria Vinall

University of Toronto, Toronto, Ontario, Canada

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site
View author's works on this site

Edward Keystone

University of Toronto, Toronto, Ontario, Canada

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site
View author's works on this site

Article
Figures & Data
Info & Metrics
eLetters
PDF

Summary

Data from a Phase 2b study suggest that baricitinib, an oral JAK1/JAK2 inhibitor, is an efficacious treatment for rheumatoid arthritis when used in combination with traditional disease-modifying antirheumatic drugs.

Rheumatoid Arthritis Clinical Trials

View Full Text

PreviousNext

Tools

Download PDF

View Full Page PDF

Citation Tools

12-Week Results of a Phase 2b Dose-Ranging Study of Baricitinib (LY3009104) in Combination with Traditional DMARDs in Patients with RA

Citation Manager Formats

BibTeX
Bookends
EasyBib
EndNote (tagged)
EndNote 8 (xml)
Medlars
Mendeley
Papers
RefWorks Tagged
Ref Manager
RIS
Zotero

Thank you for your interest in spreading the word on MD Conference Express.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Your Email *

Your Name *

Send To *

Enter multiple addresses on separate lines or separate them with commas.

You are going to email the following 12-Week Results of a Phase 2b Dose-Ranging Study of Baricitinib (LY3009104) in Combination with Traditional DMARDs in Patients with RA

Message Subject (Your Name) has sent you a message from MD Conference Express

Message Body (Your Name) thought you would like to see the MD Conference Express web site.

Your Personal Message